Open | $0.810 |
Close | $0.758 |
Volume / Avg. | 3.794M / 5.063M |
Day Range | 0.751 - 0.810 |
52 Wk Range | 0.732 - 6.870 |
Market Cap | $115.296M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 30 |
Short Interest | 14.46% |
Days to Cover | 6.14 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Seres Therapeutics (NASDAQ: MCRB) through any online brokerage.
Other companies in Seres Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Vincerx Pharma (NASDAQ:VINC), Outlook Therapeutics (NASDAQ:OTLK), Anixa Biosciences (NASDAQ:ANIX) and Galectin Therapeutics (NASDAQ:GALT).
The latest price target for Seres Therapeutics (NASDAQ: MCRB) was reported by Oppenheimer on Wednesday, March 6, 2024. The analyst firm set a price target for 5.00 expecting MCRB to rise to within 12 months (a possible 554.88% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Seres Therapeutics (NASDAQ: MCRB) is $0.7635 last updated March 18, 2024 at 7:52 PM EDT.
There are no upcoming dividends for Seres Therapeutics.
Seres Therapeutics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Seres Therapeutics.
Seres Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.